ITALFARMACO S.P.A

Company snapshot

Italfarmaco SpA, multinazionale italiana privata fondata nel 1938 con sede a Milano, opera in Italia e all’estero nel settore farmaceutico e chimico-farmaceutico attraverso società direttamente controllate e/o partecipate. Oggi il Gruppo Italfarmaco è presente con la sua attività di vendita di prodotti etici in Italia, Svizzera, Francia, Spagna, Germania, Portogallo, Grecia, Russia, Turchia, Cile,

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ITALFARMACO S.P.A. Not investment advice.

• Peer + 0 momentum

  Sarepta Therapeutics

  TA overlap score 29.2

Recent activity

Latest pipeline, patent, and corporate events for ITALFARMACO S.P.A.

1. Jun 8, 2026 Clinical update

   DSC/14/2357/50 — Phase 3

2. Jun 8, 2026 Clinical update

   DSC/08/2357/32 — Phase 3

3. Jun 8, 2026 Clinical update

   ITF2357-60 — Phase 1

4. Jun 8, 2026 Clinical update

   EFFI2021/01 — Approved

5. Jun 8, 2026 Clinical update

   DSC/11/2357/44 — Phase 2

View all clinical trial activity →

• What is ITALFARMACO S.P.A?

  Italfarmaco S.p.A is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Duchenne muscular dystrophy (DMD), JAK2V617F-positive high-risk Polycythemia Vera, Chronic myeloproliferative neoplasm, Female contraception., Duchenne Muscular Dystrop

• Is ITALFARMACO S.P.A publicly traded?

  ITALFARMACO S.P.A appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does ITALFARMACO S.P.A develop or market?

  We link 17 drug profile(s) where ITALFARMACO S.P.A is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/italfarmaco-s-p-a#company-drugs.

• What are the latest developments for ITALFARMACO S.P.A?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ITALFARMACO S.P.A focus on?

  ITALFARMACO S.P.A focuses on Duchenne muscular dystrophy (DMD), JAK2V617F-positive high-risk Polycythemia Vera, Chronic myeloproliferative neoplasm based on our analysis of their pipeline programs and drug development activities.